Scholarlink

<p>Respiratory syncytial virus (RSV) is a significant, recently recognised cause of respiratory illness in older people in whom pharmacological preventive and treatment options are lacking. Three vaccines, however, are now approved in people aged ≥ 60 years. RSVPreF (Abrysvo), RSVPreF3 OA (Arexvy) and mRNA-1345 (mResvia) each reduced the incidence of confirmed RSV infections after a single dose. Vaccines were generally well tolerated, with the incidence of severe adverse event being similar to placebo. RSV vaccination should be discussed with all older adults.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Vaccinate against respiratory syncytial virus in older adults

  • 期刊论文

  • 发表日期：

    2025年9月26日

查看全文
  • Caroline Fenton,
  • Simon Fung

摘要

Respiratory syncytial virus (RSV) is a significant, recently recognised cause of respiratory illness in older people in whom pharmacological preventive and treatment options are lacking. Three vaccines, however, are now approved in people aged ≥ 60 years. RSVPreF (Abrysvo), RSVPreF3 OA (Arexvy) and mRNA-1345 (mResvia) each reduced the incidence of confirmed RSV infections after a single dose. Vaccines were generally well tolerated, with the incidence of severe adverse event being similar to placebo. RSV vaccination should be discussed with all older adults.